WebApr 11, 2024 · The FLARE trial by Tu et al. evaluated the safety and effectiveness of percutaneous mechanical thrombectomy using the FlowTriever ® System in patients with acute intermediate-risk pulmonary embolism. Patients with symptomatic, computed tomography-documented PE and right ventricular (RV)/left ventricular (LV) ratios ≥0.9 … WebJan 12, 2024 · This trial is designed to produce definitive evidence to change standard of care.” Inari Medical noted that DEFIANCE, which is the company’s second RCT, will run in parallel to the PEERLESS trial that is comparing the FlowTriever system to catheter-directed thrombolytics in pulmonary embolism.
A Prospective, Single-Arm, Multicenter Trial of Catheter …
WebAug 30, 2024 · DEFIANCE is Inari’s second RCT and it will run in parallel to the PEERLESS trial. PEERLESS commenced earlier this year and compares FlowTriever to catheter-directed thrombolytics in pulmonary ... WebFeb 15, 2024 · February 15, 2024—Inari Medical, Inc. announced that the first patient has been enrolled in the PEERLESS randomized controlled trial that aims to compare the outcomes of patients with intermediate-high risk pulmonary embolism (PE) treated with the FlowTriever system versus catheter-directed thrombolysis (CDT). flug berlin istanbul turkish airlines
Inari Medical’s FlowTriever System Studied in FLAME Trial for …
WebThe “re-purposing” of these devices for venous clot is sub-optimal due to clot morphology and vessel sizes. As a result, treatments include, or rely exclusively upon, thrombolytic drugs and their inherent bleeding risks. Inari ClotTriever Thrombectomy System WebAug 30, 2024 · August 30, 2024—Inari Medical, Inc. announced the planned enrollment of the DEFIANCE randomized controlled trial (RCT). The trial will compare clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with the company’s ClotTriever system versus treatment with anticoagulation only. WebApr 13, 2024 · April 13, 2024 - 4:01 pm. IRVINE, Calif., April 13, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2024 financial results on Wednesday, … green eggs and ham teaching resources